152 related articles for article (PubMed ID: 37038213)
1. Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders.
Régy M; Dugravot A; Sabia S; Bouaziz-Amar E; Paquet C; Hanseeuw B; Singh-Manoux A; Dumurgier J
Alzheimers Res Ther; 2023 Apr; 15(1):77. PubMed ID: 37038213
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease.
Delmotte K; Schaeverbeke J; Poesen K; Vandenberghe R
Alzheimers Res Ther; 2021 Apr; 13(1):84. PubMed ID: 33879243
[TBL] [Abstract][Full Text] [Related]
3. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
4. β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.
Rosenberg A; Öhlund-Wistbacka U; Hall A; Bonnard A; Hagman G; Rydén M; Thunborg C; Wiggenraad F; Sandebring-Matton A; Solomon A; Kivipelto M
Neurology; 2022 Nov; 99(19):e2102-e2113. PubMed ID: 36130840
[TBL] [Abstract][Full Text] [Related]
5. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
Bucci M; Chiotis K; Nordberg A;
Mol Psychiatry; 2021 Oct; 26(10):5888-5898. PubMed ID: 34593971
[TBL] [Abstract][Full Text] [Related]
7. CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease.
Boumenir A; Cognat E; Sabia S; Hourregue C; Lilamand M; Dugravot A; Bouaziz-Amar E; Laplanche JL; Hugon J; Singh-Manoux A; Paquet C; Dumurgier J
Alzheimers Res Ther; 2019 Mar; 11(1):29. PubMed ID: 30922415
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
[TBL] [Abstract][Full Text] [Related]
9. Exploring the ATN classification system using brain morphology.
Heinzinger N; Maass A; Berron D; Yakupov R; Peters O; Fiebach J; Villringer K; Preis L; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Bartels C; Jessen F; Maier F; Glanz W; Buerger K; Janowitz D; Perneczky R; Rauchmann BS; Teipel S; Killimann I; Göerß D; Laske C; Munk MH; Spottke A; Roy N; Heneka MT; Brosseron F; Dobisch L; Ewers M; Dechent P; Haynes JD; Scheffler K; Wolfsgruber S; Kleineidam L; Schmid M; Berger M; Düzel E; Ziegler G;
Alzheimers Res Ther; 2023 Mar; 15(1):50. PubMed ID: 36915139
[TBL] [Abstract][Full Text] [Related]
10. Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies.
van de Beek M; Ooms FAH; Ebenau JL; Barkhof F; Scheltens P; Teunissen CE; van Harten AC; van der Flier WM; Lemstra AW
Neurology; 2022 Mar; 98(12):e1262-e1272. PubMed ID: 35074893
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of imaging-based ATN profiles in a memory clinic cohort.
Peretti DE; Ribaldi F; Scheffler M; Chicherio C; Frisoni GB; Garibotto V
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3313-3323. PubMed ID: 37358619
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
13. CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology.
Cousins KAQ; Arezoumandan S; Shellikeri S; Ohm D; Shaw LM; Grossman M; Wolk D; McMillan CT; Chen-Plotkin A; Lee E; Trojanowski JQ; Zetterberg H; Blennow K; Irwin DJ
Neurology; 2022 Nov; 99(20):e2303-e2312. PubMed ID: 36041863
[TBL] [Abstract][Full Text] [Related]
14. Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau.
Lafirdeen ASM; Cognat E; Sabia S; Hourregue C; Lilamand M; Dugravot A; Bouaziz-Amar E; Laplanche JL; Hugon J; Singh-Manoux A; Paquet C; Dumurgier J
PLoS One; 2019; 14(5):e0217026. PubMed ID: 31086391
[TBL] [Abstract][Full Text] [Related]
15. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers.
Baldeiras I; Silva-Spínola A; Lima M; Leitão MJ; Durães J; Vieira D; Tábuas-Pereira M; Cruz VT; Rocha R; Alves L; Machado Á; Milheiro M; Santiago B; Santana I
J Alzheimers Dis; 2022; 90(1):419-432. PubMed ID: 36120784
[TBL] [Abstract][Full Text] [Related]
17. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
Ebenau JL; Timmers T; Wesselman LMP; Verberk IMW; Verfaillie SCJ; Slot RER; van Harten AC; Teunissen CE; Barkhof F; van den Bosch KA; van Leeuwenstijn M; Tomassen J; Braber AD; Visser PJ; Prins ND; Sikkes SAM; Scheltens P; van Berckel BNM; van der Flier WM
Neurology; 2020 Jul; 95(1):e46-e58. PubMed ID: 32522798
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal change in ATN biomarkers in cognitively normal individuals.
Ebenau JL; Visser D; Kroeze LA; van Leeuwenstijn MSSA; van Harten AC; Windhorst AD; Golla SVS; Boellaard R; Scheltens P; Barkhof F; van Berckel BNM; van der Flier WM
Alzheimers Res Ther; 2022 Sep; 14(1):124. PubMed ID: 36057616
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Cognitive Progression in Individuals with Mild Cognitive Impairment Using Radiomics as an Improvement of the ATN System: A Five-Year Follow-Up Study.
Song R; Wu X; Liu H; Guo D; Tang L; Zhang W; Feng J; Li C
Korean J Radiol; 2022 Jan; 23(1):89-100. PubMed ID: 34983097
[TBL] [Abstract][Full Text] [Related]
20. Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies.
Rådestig MA; Skoog J; Zetterberg H; Kern J; Zettergren A; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
J Alzheimers Dis; 2021; 79(1):225-235. PubMed ID: 33216028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]